SWAV vs. PODD, SOLV, TFX, GMED, PEN, BAX, STVN, GKOS, HAE, and MMSI
Should you be buying Shockwave Medical stock or one of its competitors? The main competitors of Shockwave Medical include Insulet (PODD), Solventum (SOLV), Teleflex (TFX), Globus Medical (GMED), Penumbra (PEN), Baxter International (BAX), Stevanato Group (STVN), Glaukos (GKOS), Haemonetics (HAE), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
Insulet (NASDAQ:PODD) and Shockwave Medical (NASDAQ:SWAV) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
In the previous week, Insulet had 16 more articles in the media than Shockwave Medical. MarketBeat recorded 23 mentions for Insulet and 7 mentions for Shockwave Medical. Insulet's average media sentiment score of 1.28 beat Shockwave Medical's score of 0.19 indicating that Shockwave Medical is being referred to more favorably in the news media.
Shockwave Medical has a net margin of 20.75% compared to Shockwave Medical's net margin of 13.14%. Shockwave Medical's return on equity of 34.06% beat Insulet's return on equity.
Insulet has higher revenue and earnings than Shockwave Medical. Insulet is trading at a lower price-to-earnings ratio than Shockwave Medical, indicating that it is currently the more affordable of the two stocks.
Insulet presently has a consensus price target of $239.44, suggesting a potential upside of 27.86%. Shockwave Medical has a consensus price target of $309.11, suggesting a potential downside of 6.37%. Given Shockwave Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Insulet is more favorable than Shockwave Medical.
Insulet received 578 more outperform votes than Shockwave Medical when rated by MarketBeat users. Likewise, 66.05% of users gave Insulet an outperform vote while only 55.83% of users gave Shockwave Medical an outperform vote.
95.4% of Shockwave Medical shares are owned by institutional investors. 0.5% of Insulet shares are owned by company insiders. Comparatively, 3.4% of Shockwave Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Insulet has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Shockwave Medical has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
Summary
Insulet beats Shockwave Medical on 10 of the 18 factors compared between the two stocks.
Get Shockwave Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWAV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SWAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shockwave Medical Competitors List
Related Companies and Tools
